JP2004526412A5 - - Google Patents

Download PDF

Info

Publication number
JP2004526412A5
JP2004526412A5 JP2002529483A JP2002529483A JP2004526412A5 JP 2004526412 A5 JP2004526412 A5 JP 2004526412A5 JP 2002529483 A JP2002529483 A JP 2002529483A JP 2002529483 A JP2002529483 A JP 2002529483A JP 2004526412 A5 JP2004526412 A5 JP 2004526412A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
polypeptide
amino acid
normal control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002529483A
Other languages
Japanese (ja)
Other versions
JP2004526412A (en
JP4451059B2 (en
Filing date
Publication date
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/en
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Application filed filed Critical
Priority claimed from PCT/US2001/027099 external-priority patent/WO2002024888A2/en
Publication of JP2004526412A publication Critical patent/JP2004526412A/en
Publication of JP2004526412A5 publication Critical patent/JP2004526412A5/ja
Publication of JP4451059B2 publication Critical patent/JP4451059B2/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 配列番号：１０８に示されるアミノ酸配列を持つポリペプチドをコードするヌクレオチド配列を含んでなる、結腸腫瘍マーカーとして使用するための単離された核酸であって、結腸腫瘍で過剰発現している核酸。
【請求項２】 配列番号：１０７に示されるヌクレオチド配列を含んでなる単離された核酸であって、結腸腫瘍で過剰発現している核酸。
【請求項３】 請求項１に記載の核酸を含んでなるベクター。
【請求項４】 当該ベクターで形質転換された宿主細胞によって認識されるコントロール配列に作用可能に結合した請求項３に記載のベクター。
【請求項５】 請求項３に記載のベクターを含んでなる宿主細胞。
【請求項６】 配列番号：１０８に示されるアミノ酸配列を含んでなる、結腸腫瘍マーカーとして使用するための単離されたポリペプチドであって、結腸腫瘍で過剰発現しているポリペプチド。
【請求項７】 配列番号：１０８に示されるアミノ酸配列を持つポリペプチドを含んでなるキメラ分子であって、異種アミノ酸配列へ融合したキメラ分子。
【請求項８】 前記異種アミノ酸配列がエピトープタグ配列である、請求項７に記載のキメラ分子。
【請求項９】 前記異種アミノ酸配列が免疫グロブリンのＦｃ領域である、請求項７に記載のキメラ分子。
【請求項１０】請求項６に記載されたポリペプチドに特異的に結合する抗体。
【請求項１１】前記抗体がモノクローナル抗体、ヒト化抗体、ヒト抗体又は単鎖抗体である、請求項１０に記載の抗体。
【請求項１２】哺乳類から得られた試験結腸試料中の配列番号：１０８に示されるアミノ酸配列を含んでなるポリペプチドをコードする核酸の発現レベルを正常結腸細胞と比較して決定することを含んでなる、試験結腸試料中の癌細胞の存在を検出する方法。
【請求項１３】試験結腸試料または正常結腸試料が組織試料である、請求項１２に記載の方法。
【請求項１４】試験結腸試料及び正常結腸試料から得られた核酸を、配列番号：１０８に示されるアミノ酸配列を含んでなるポリペプチドをコードする核酸に特異的なプローブを１つもしくはそれ以上用いてハイブリダイゼーションすることにより、そのレベルを決定する請求項１２に記載の方法。
【請求項１５】ハイブリダイゼーションが高度の緊縮性条件下で行われる、請求項１４に記載の方法。
【請求項１６】試験結腸試料及び正常結腸試料から得られた核酸がcDNAである、請求項１４に記載の方法。
【請求項１７】試験結腸試料及び正常結腸試料から得られた核酸がマイクロアレイに置かれた、請求項１６に記載の方法。
【請求項１８】正常結腸試料と比較して試験結腸試料中の配列番号：１０８に示されるアミノ酸配列を含んでなるポリペプチドの発現レベルを決定することを含んでなる、試験結腸試料中の癌細胞の存在を検出する方法。
【請求項１９】配列番号：１０８に示されるアミノ酸配列を含んでなるポリペプチドに特異的に結合する抗体を用いて過剰発現を検出する請求項１８に記載の方法。
【請求項２０】前記抗体がモノクローナル抗体、ヒト抗体、ヒト化抗体又は単鎖抗体である、請求項１９に記載の方法。
【請求項２１】前記抗体が抗体断片である、請求項１９に記載の方法。
【請求項２２】前記抗体が標識されている、請求項１９に記載の方法。
[Claims]
1. A SEQ ID NO: polypeptide de having the amino acid sequence shown in 108 comprising a nucleotide sequence encoding a an isolated nucleic acid for use as a colon tumor marker, overexpressed in colon tumors Nucleic acid.
2. An isolated nucleic acid comprising the nucleotide sequence shown in SEQ ID NO: 107, which is overexpressed in a colon tumor.
3. A vector comprising the nucleic acid according to claim 1.
4. The vector of claim 3 , operably linked to a control sequence recognized by a host cell transformed with the vector.
5. A host cell comprising the vector of claim 3 .
6. SEQ ID NO: 108 shown in comprising a luer amino acid sequences, an isolated polypeptide for use as a colon tumor marker, polypeptide overexpressed in colon tumors .
7. SEQ ID NO: 108 a chimeric molecule comprising a polypeptide de having the amino acid sequence shown in, the chimeric molecule fused to a heterologous amino acid sequence.
8. The chimeric molecule of claim 7 , wherein the heterologous amino acid sequence is an epitope tag sequence.
9. The chimeric molecule of claim 7 , wherein the heterologous amino acid sequence is an immunoglobulin Fc region.
10. An antibody that specifically binds to the polypeptide according to claim 6 .
11. The antibody according to claim 10 , wherein the antibody is a monoclonal antibody, a humanized antibody, a human antibody or a single chain antibody.
12. Determination of the expression level of a nucleic acid encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 108 in a test colon sample obtained from a mammal as compared to normal colon cells. A method for detecting the presence of cancer cells in a test colon sample.
13. The method of claim 12 , wherein the test colon sample or normal colon sample is a tissue sample.
14. A nucleic acid obtained from a test colon sample and a normal colon sample using one or more probes specific for a nucleic acid encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 108. The method according to claim 12 , wherein the level is determined by hybridization.
15. Hybridization is carried out at high stringency conditions, method according to claim 14.
16. The method according to claim 14 , wherein the nucleic acid obtained from the test colon sample and the normal colon sample is cDNA.
17. The method of claim 16 , wherein the nucleic acids obtained from the test colon sample and the normal colon sample are placed in a microarray.
18. A cancer in a test colon sample comprising determining the expression level of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 108 in a test colon sample as compared to a normal colon sample. A method of detecting the presence of a cell.
19. The method according to claim 18 , wherein overexpression is detected using an antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 108.
20. The method according to claim 19 , wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody or a single chain antibody.
21. The method of claim 19 , wherein the antibody is an antibody fragment.
22. The method of claim 19 , wherein the antibody is labeled.

表８
分子 過剰発現した所： 次の正常対照と比較した：
PRO240 乳房腫瘍 一般正常対照
PRO240 肺腫瘍 一般正常対照

PRO256 結腸腫瘍 一般正常対照
PRO256 肺腫瘍 一般正常対照
PRO256 乳房腫瘍 一般正常対照

PRO306 結腸腫瘍 一般正常対照
PRO306 肺腫瘍 一般正常対照

PRO540 肺腫瘍 一般正常対照
PRO540 結腸腫瘍 一般正常対照

PRO773 乳房腫瘍 一般正常対照
PRO773 結腸腫瘍 一般正常対照

PRO698 結腸腫瘍 一般正常対照
PRO698 乳房腫瘍 一般正常対照
PRO698 肺腫瘍 一般正常対照
PRO698 前立腺腫瘍 一般正常対照
PRO698 直腸腫瘍 一般正常対照

PRO3567 結腸腫瘍 一般正常対照
PRO3567 乳房腫瘍 一般正常対照
PRO3567 肺腫瘍 一般正常対照

PRO826 結腸腫瘍 一般正常対照
PRO826 肺腫瘍 一般正常対照
PRO826 乳房腫瘍 一般正常対照
PRO826 直腸腫瘍 一般正常対照
PRO826 肝腫瘍 一般正常対照

PRO1002 結腸腫瘍 一般正常対照
PRO1002 肺腫瘍 一般正常対照

PRO1068 結腸腫瘍 一般正常対照
PRO1068 乳房腫瘍 一般正常対照

PRO1030 結腸腫瘍 一般正常対照
PRO1030 乳房腫瘍 一般正常対照
PRO1030 肺腫瘍 一般正常対照
PRO1030 前立腺腫瘍 一般正常対照
PRO1030 直腸腫瘍 一般正常対照

PRO4397 結腸腫瘍 一般正常対照
PRO4397 乳房腫瘍 一般正常対照

PRO4344 結腸腫瘍 一般正常対照
PRO4344 肺腫瘍 一般正常対照
PRO4344 直腸腫瘍 一般正常対照

PRO4407 結腸腫瘍 一般正常対照
PRO4407 乳房腫瘍 一般正常対照
PRO4407 肺腫瘍 一般正常対照
PRO4407 肝腫瘍 一般正常対照
PRO4407 直腸腫瘍 一般正常対照

PRO4316 結腸腫瘍 一般正常対照
PRO4316 前立腺腫瘍 一般正常対照

PRO5775 結腸腫瘍 一般正常対照

PRO6016 結腸腫瘍 一般正常対照

PRO4980 乳房腫瘍 一般正常対照
PRO4980 結腸腫瘍 一般正常対照
PRO4980 肺腫瘍 一般正常対照

PRO6018 結腸腫瘍 一般正常対照

PRO7168 結腸腫瘍 一般正常対照

PRO6000 結腸腫瘍 一般正常対照

PRO6006 結腸腫瘍 一般正常対照

PRO5800 結腸腫瘍 一般正常対照
PRO5800 乳房腫瘍 一般正常対照
PRO5800 肺腫瘍 一般正常対照
PRO5800 直腸腫瘍 一般正常対照

PRO7476 結腸腫瘍 一般正常対照

PRO10268 結腸腫瘍 一般正常対照

PRO6496 結腸腫瘍 一般正常対照
PRO6496 乳房腫瘍 一般正常対照
PRO6496 肺腫瘍 一般正常対照

PRO7422 結腸腫瘍 一般正常対照

PRO7431 結腸腫瘍 一般正常対照

PRO28633 結腸腫瘍 一般正常対照
PRO28633 肺腫瘍 一般正常対照
PRO28633 肝腫瘍 一般正常対照

PRO21485 結腸腫瘍 一般正常対照

PRO28700 乳房腫瘍 一般正常対照
PRO28700 肺腫瘍 一般正常対照
PRO28700 結腸腫瘍 一般正常対照

PRO34012 結腸腫瘍 一般正常対照
PRO34012 肺腫瘍 一般正常対照

PRO34003 結腸腫瘍 一般正常対照
PRO34003 肺腫瘍 一般正常対照

PRO34001 結腸腫瘍 一般正常対照

PRO34009 結腸腫瘍 一般正常対照
PRO34009 乳房腫瘍 一般正常対照
PRO34009 肺腫瘍 一般正常対照
PRO34009 直腸腫瘍 一般正常対照

PRO34192 結腸腫瘍 一般正常対照

PRO34564 結腸腫瘍 一般正常対照

PRO35444 結腸腫瘍 一般正常対照

PRO5998 結腸腫瘍 一般正常対照
PRO5998 肺腫瘍 一般正常対照
PRO5998 腎腫瘍 一般正常対照

PRO19651 結腸腫瘍 一般正常対照

PRO20221 肝腫瘍 一般正常対照

PRO21434 肝腫瘍 一般正常対照
Table 8
Where the molecule is overexpressed: compared to the following normal controls:
PRO240 Breast tumor General normal control
PRO240 Lung tumor General normal control

PRO256 colon tumor General normal control
PRO256 Lung tumor General normal control
PRO256 Breast tumor General normal control

PRO306 colon tumor General normal control
PRO306 Lung tumor General normal control

PRO540 Lung tumor General normal control
PRO540 colon tumor General normal control

PRO773 Breast tumor General normal control
PRO773 colon tumor General normal control

PRO698 Colon tumor General normal control
PRO698 Breast tumor General normal control
PRO698 Lung tumor General normal control
PRO698 Prostate tumor General normal control
PRO698 Rectal tumor General normal control

PRO3567 Colon tumor General normal control
PRO3567 Breast tumor General normal control
PRO3567 Lung tumor General normal control

PRO826 colon tumor General normal control
PRO826 Lung tumor General normal control
PRO826 Breast tumor General normal control
PRO826 Rectal tumor General normal control
PRO826 Liver tumor General normal control

PRO1002 Colon tumor General normal control
PRO1002 Lung tumor General normal control

PRO1068 Colon tumor General normal control
PRO1068 Breast tumor General normal control

PRO1030 Colon tumor General normal control
PRO1030 Breast tumor General normal control
PRO1030 Lung tumor General normal control
PRO1030 Prostate tumor General normal control
PRO1030 Rectal tumor General normal control

PRO4397 Colon tumor General normal control
PRO4397 Breast tumor General normal control

PRO4344 Colon tumor General normal control
PRO4344 Lung tumor General normal control
PRO4344 Rectal tumor General normal control

PRO4407 Colon tumor General normal control
PRO4407 Breast tumor General normal control
PRO4407 Lung tumor General normal control
PRO4407 Liver tumor General normal control
PRO4407 Rectal tumor General normal control

PRO4316 Colon tumor General normal control
PRO4316 Prostate tumor General normal control

PRO5775 colon tumor General normal control

PRO6016 colon tumor General normal control

PRO4980 Breast tumor General normal control
PRO4980 Colon tumor General normal control
PRO4980 Lung tumor General normal control

PRO6018 Colon tumor General normal control

PRO7168 Colon tumor General normal control

PRO6000 colon tumor General normal control

PRO6006 Colon tumor General normal control

PRO5800 colon tumor General normal control
PRO5800 Breast tumor General normal control
PRO5800 Lung tumor General normal control
PRO5800 Rectal tumor General normal control

PRO7476 Colon tumor General normal control

PRO10268 Colon tumor General normal control

PRO6496 colon tumor General normal control
PRO6496 Breast tumor General normal control
PRO6496 Lung tumor General normal control

PRO7422 Colon tumor General normal control

PRO7431 Colon tumor General normal control

PRO28633 Colon tumor General normal control
PRO28633 Lung tumor General normal control
PRO28633 Liver tumor General normal control

PRO21485 Colon tumor General normal control

PRO28700 Breast tumor General normal control
PRO28700 Lung tumor General normal control
PRO28700 Colon tumor General normal control

PRO34012 Colon tumor General normal control
PRO34012 Lung tumor General normal control

PRO34003 Colon tumor General normal control
PRO34003 Lung tumor General normal control

PRO34001 Colon tumor General normal control

PRO34009 Colon tumor General normal control
PRO34009 Breast tumor General normal control
PRO34009 Lung tumor General normal control
PRO34009 Rectal tumor General normal control

PRO34192 Colon tumor General normal control

PRO34564 Colon tumor General normal control

PRO35444 Colon tumor General normal control

PRO5998 Colon tumor General normal control
PRO5998 Lung tumor General normal control
PRO5998 Kidney tumor General normal control

PRO19651 Colon tumor General normal control

PRO20221 Liver tumor General normal control

PRO21434 Liver tumor General normal control

Claims (26)

Figure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 及び Figure 114 (配列番号:114)に示されるアミノ酸配列からなる群から選択されるアミノ酸配列をコードするヌクレオチド配列に対して少なくとも８０％の核酸配列同一性を有する単離された核酸。Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO: 10), Figure 12 (SEQ ID NO: : 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54), Figure 56 (SEQ ID NO: 56) ), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 (SEQ ID NO: 66), Figure 68 ( (SEQ ID NO: 68), Figure 70 (SEQ ID NO: : 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) and Figure 114 (SEQ ID NO: 114) An isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence encoding an amino acid sequence selected from the group consisting of the amino acid sequences shown in Figure 1 (配列番号:1), Figure 3 (配列番号:3), Figure 5 (配列番号:5), Figure 7 (配列番号:7), Figure 9 (配列番号:9), Figure 11 (配列番号:11), Figure 13 (配列番号:13), Figure 15 (配列番号:15), Figure 17 (配列番号:17), Figure 19 (配列番号:19), Figure 21 (配列番号:21), Figure 23 (配列番号:23), Figure 25 (配列番号:25), Figure 27 (配列番号:27), Figure 29 (配列番号:29), Figure 31 (配列番号:31), Figure 33 (配列番号:33), Figure 35 (配列番号:35), Figure 37 (配列番号:37), Figure 39 (配列番号:39), Figure 41 (配列番号:41), Figure 43 (配列番号:43), Figure 45 (配列番号:45), Figure 47 (配列番号:47), Figure 49 (配列番号:49), Figure 51 (配列番号:51), Figure 53 (配列番号:53), Figure 55 (配列番号:55), Figure 57 (配列番号:57), Figure 59 (配列番号:59), Figure 61 (配列番号:61), Figure 63 (配列番号:63), Figure 65 (配列番号:65), Figure 67 (配列番号:67), Figure 69 (配列番号:69), Figure 71 (配列番号:71), Figure 73 (配列番号:73), Figures 75A-75B (配列番号:75), Figure 77 (配列番号:77), Figure 79 (配列番号:79), Figure 81 (配列番号:81), Figure 83 (配列番号:83), Figure 85 (配列番号:85), Figure 87 (配列番号:87), Figure 89 (配列番号:89), Figure 91 (配列番号:91), Figure 93 (配列番号:93), Figure 95 (配列番号:95), Figure 97 (配列番号:97), Figure 99 (配列番号:99), Figure 101 (配列番号:101), Figure 103 (配列番号:103), Figure 105 (配列番号:105), Figure 107 (配列番号:107), Figure 109 (配列番号:109), Figure 111 (配列番号:111) 及び Figure 113 (配列番号:113)に示されるヌクレオチド配列からなる群から選択されるヌクレオチド配列に対して少なくとも８０％の核酸配列同一性を有する単離された核酸。Figure 1 (SEQ ID NO: 1), Figure 3 (SEQ ID NO: 3), Figure 5 (SEQ ID NO: 5), Figure 7 (SEQ ID NO: 7), Figure 9 (SEQ ID NO: 9), Figure 11 (SEQ ID NO: : 11), Figure 13 (SEQ ID NO: 13), Figure 15 (SEQ ID NO: 15), Figure 17 (SEQ ID NO: 17), Figure 19 (SEQ ID NO: 19), Figure 21 (SEQ ID NO: 21), Figure 23 (SEQ ID NO: 23), Figure 25 (SEQ ID NO: 25), Figure 27 (SEQ ID NO: 27), Figure 29 (SEQ ID NO: 29), Figure 31 (SEQ ID NO: 31), Figure 33 (SEQ ID NO: 33), Figure 35 (SEQ ID NO: 35), Figure 37 (SEQ ID NO: 37), Figure 39 (SEQ ID NO: 39), Figure 41 (SEQ ID NO: 41), Figure 43 (SEQ ID NO: 43), Figure 45 (SEQ ID NO: 45), Figure 47 (SEQ ID NO: 47), Figure 49 (SEQ ID NO: 49), Figure 51 (SEQ ID NO: 51), Figure 53 (SEQ ID NO: 53), Figure 55 (SEQ ID NO: 55 ), Figure 57 (SEQ ID NO: 57), Figure 59 (SEQ ID NO: 59), Figure 61 (SEQ ID NO: 61), Figure 63 (SEQ ID NO: 63), Figure 65 (SEQ ID NO: 65), Figure 67 ( (SEQ ID NO: 67), Figure 69 (SEQ ID NO :) 69), Figure 71 (SEQ ID NO: 71), Figure 73 (SEQ ID NO: 73), Figures 75A-75B (SEQ ID NO: 75), Figure 77 (SEQ ID NO: 77), Figure 79 (SEQ ID NO: 79), Figure 81 (SEQ ID NO: 81), Figure 83 (SEQ ID NO: 83), Figure 85 (SEQ ID NO: 85), Figure 87 (SEQ ID NO: 87), Figure 89 (SEQ ID NO: 89), Figure 91 (SEQ ID NO: : 91), Figure 93 (SEQ ID NO: 93), Figure 95 (SEQ ID NO: 95), Figure 97 (SEQ ID NO: 97), Figure 99 (SEQ ID NO: 99), Figure 101 (SEQ ID NO: 101), Figure 103 (SEQ ID NO: 103), Figure 105 (SEQ ID NO: 105), Figure 107 (SEQ ID NO: 107), Figure 109 (SEQ ID NO: 109), Figure 111 (SEQ ID NO: 111) and Figure 113 (SEQ ID NO: 113) an isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequences set forth in 113). Figure 1 (配列番号:1), Figure 3 (配列番号:3), Figure 5 (配列番号:5), Figure 7 (配列番号:7), Figure 9 (配列番号:9), Figure 11 (配列番号:11), Figure 13 (配列番号:13), Figure 15 (配列番号:15), Figure 17 (配列番号:17), Figure 19 (配列番号:19), Figure 21 (配列番号:21), Figure 23 (配列番号:23), Figure 25 (配列番号:25), Figure 27 (配列番号:27), Figure 29 (配列番号:29), Figure 31 (配列番号:31), Figure 33 (配列番号:33), Figure 35 (配列番号:35), Figure 37 (配列番号:37), Figure 39 (配列番号:39), Figure 41 (配列番号:41), Figure 43 (配列番号:43), Figure 45 (配列番号:45), Figure 47 (配列番号:47), Figure 49 (配列番号:49), Figure 51 (配列番号:51), Figure 53 (配列番号:53), Figure 55 (配列番号:55), Figure 57 (配列番号:57), Figure 59 (配列番号:59), Figure 61 (配列番号:61), Figure 63 (配列番号:63), Figure 65 (配列番号:65), Figure 67 (配列番号:67), Figure 69 (配列番号:69), Figure 71 (配列番号:71), Figure 73 (配列番号:73), Figures 75A-75B (配列番号:75), Figure 77 (配列番号:77), Figure 79 (配列番号:79), Figure 81 (配列番号:81), Figure 83 (配列番号:83), Figure 85 (配列番号:85), Figure 87 (配列番号:87), Figure 89 (配列番号:89), Figure 91 (配列番号:91), Figure 93 (配列番号:93), Figure 95 (配列番号:95), Figure 97 (配列番号:97), Figure 99 (配列番号:99), Figure 101 (配列番号:101), Figure 103 (配列番号:103), Figure 105 (配列番号:105), Figure 107 (配列番号:107), Figure 109 (配列番号:109), Figure 111 (配列番号:111) 及び Figure 113 (配列番号:113)に示されるヌクレオチド配列の完全長コーディング配列からなる群から選択されるヌクレオチド配列に対して少なくとも８０％の核酸配列同一性を有する単離された核酸。Figure 1 (SEQ ID NO: 1), Figure 3 (SEQ ID NO: 3), Figure 5 (SEQ ID NO: 5), Figure 7 (SEQ ID NO: 7), Figure 9 (SEQ ID NO: 9), Figure 11 (SEQ ID NO: : 11), Figure 13 (SEQ ID NO: 13), Figure 15 (SEQ ID NO: 15), Figure 17 (SEQ ID NO: 17), Figure 19 (SEQ ID NO: 19), Figure 21 (SEQ ID NO: 21), Figure 23 (SEQ ID NO: 23), Figure 25 (SEQ ID NO: 25), Figure 27 (SEQ ID NO: 27), Figure 29 (SEQ ID NO: 29), Figure 31 (SEQ ID NO: 31), Figure 33 (SEQ ID NO: 33), Figure 35 (SEQ ID NO: 35), Figure 37 (SEQ ID NO: 37), Figure 39 (SEQ ID NO: 39), Figure 41 (SEQ ID NO: 41), Figure 43 (SEQ ID NO: 43), Figure 45 (SEQ ID NO: 45), Figure 47 (SEQ ID NO: 47), Figure 49 (SEQ ID NO: 49), Figure 51 (SEQ ID NO: 51), Figure 53 (SEQ ID NO: 53), Figure 55 (SEQ ID NO: 55 ), Figure 57 (SEQ ID NO: 57), Figure 59 (SEQ ID NO: 59), Figure 61 (SEQ ID NO: 61), Figure 63 (SEQ ID NO: 63), Figure 65 (SEQ ID NO: 65), Figure 67 ( (SEQ ID NO: 67), Figure 69 (SEQ ID NO :) 69), Figure 71 (SEQ ID NO: 71), Figure 73 (SEQ ID NO: 73), Figures 75A-75B (SEQ ID NO: 75), Figure 77 (SEQ ID NO: 77), Figure 79 (SEQ ID NO: 79), Figure 81 (SEQ ID NO: 81), Figure 83 (SEQ ID NO: 83), Figure 85 (SEQ ID NO: 85), Figure 87 (SEQ ID NO: 87), Figure 89 (SEQ ID NO: 89), Figure 91 (SEQ ID NO: : 91), Figure 93 (SEQ ID NO: 93), Figure 95 (SEQ ID NO: 95), Figure 97 (SEQ ID NO: 97), Figure 99 (SEQ ID NO: 99), Figure 101 (SEQ ID NO: 101), Figure 103 (SEQ ID NO: 103), Figure 105 (SEQ ID NO: 105), Figure 107 (SEQ ID NO: 107), Figure 109 (SEQ ID NO: 109), Figure 111 (SEQ ID NO: 111) and Figure 113 (SEQ ID NO: 113) an isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in 113). 表７に示される任意のＡＴＣＣ登録番号のもとに寄託されたＤＮＡの完全長コーディング配列に対して少なくとも８０％の核酸配列同一性を有する単離された核酸。An isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of DNA deposited under any ATCC accession number shown in Table 7. 請求項１の核酸を含むベクター。A vector comprising the nucleic acid of claim 1. 請求項５のベクターを含む宿主細胞。A host cell comprising the vector of claim 5. 前記細胞がＣＨＯ細胞である請求項６の宿主細胞。The host cell of claim 6, wherein the cell is a CHO cell. 前記細胞が大腸菌である請求項６の宿主細胞。The host cell according to claim 6, wherein the cell is Escherichia coli. 前記細胞が酵母菌である請求項６の宿主細胞。The host cell according to claim 6, wherein the cell is a yeast. ＰＲＯポリペプチドの発現に適した条件で請求項６の宿主細胞を培養し、細胞培地からＰＲＯポリペプチドを回収することを含むＰＲＯポリペプチドの生成方法。A method for producing a PRO polypeptide comprising culturing the host cell of claim 6 under conditions suitable for expression of the PRO polypeptide, and recovering the PRO polypeptide from the cell culture medium. Figure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 及び Figure 114 (配列番号:114)に示されるアミノ酸配列からなる群から選択されるアミノ酸配列に対して少なくとも８０％のアミノ酸配列同一性を有する単離されたポリペプチド。Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO: 10), Figure 12 (SEQ ID NO: : 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54), Figure 56 (SEQ ID NO: 56) ), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 (SEQ ID NO: 66), Figure 68 ( (SEQ ID NO: 68), Figure 70 (SEQ ID NO: : 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) and Figure 114 (SEQ ID NO: 114) An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequences shown in 表７に示される任意のＡＴＣＣ登録番号のもとに寄託されたＤＮＡの完全長コーディング配列によりコードされるアミノ酸配列に対して少なくとも８０％のアミノ酸配列同一性を有する単離されたポリぺプチド。An isolated polypeptide having at least 80% amino acid sequence identity to the amino acid sequence encoded by the full-length coding sequence of DNA deposited under any ATCC accession number shown in Table 7. 異種アミノ酸配列に融合した請求項１１に記載のポリペプチドを含むキメラ分子。A chimeric molecule comprising the polypeptide of claim 11 fused to a heterologous amino acid sequence. 前記異種アミノ酸配列がエピトープタグ配列である、請求項１３のキメラ分子。14. The chimeric molecule of claim 13, wherein the heterologous amino acid sequence is an epitope tag sequence. 前記異種アミノ酸配列が免疫グロブリンのＦｃ領域である、請求項１３のキメラ分子。14. The chimeric molecule of claim 13, wherein the heterologous amino acid sequence is an immunoglobulin Fc region. 請求項１１に記載のポリペプチドに特異的に結合する抗体。An antibody that specifically binds to the polypeptide of claim 11. 前記抗体がモノクローナル抗体、ヒト化抗体又は一本鎖抗体である、請求項１６の抗体。The antibody of claim 16, wherein the antibody is a monoclonal antibody, a humanized antibody or a single chain antibody. (a) 連結するシグナルペプチドを欠くFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドをコードするヌクレオチド配列；
(b)連結するシグナルペプチドを有するFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドの細胞外ドメインをコードするヌクレオチド配列；又は
(c)連結するシグナルペプチドを欠くFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドの細胞外ドメインをコードするヌクレオチド配列：
に対して少なくとも８０％の核酸配列同一性を有する単離された核酸。(a) Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO :) : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Fi gure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or nucleotide sequence encoding the polypeptide shown in Figure 114 (SEQ ID NO: 114);
(b) Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO :) : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Figure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or a nucleotide sequence encoding the extracellular domain of the polypeptide shown in Figure 114 (SEQ ID NO: 114); or
(c) Lacking signal peptide to be linked Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO: : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Fig ure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or nucleotide sequence encoding the extracellular domain of the polypeptide shown in Figure 114 (SEQ ID NO: 114):
An isolated nucleic acid having at least 80% nucleic acid sequence identity to. (a)連結するシグナルペプチドを欠くFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドのアミノ酸配列；
(b)連結するシグナルペプチドを有するFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドの細胞外ドメインのアミノ酸配列；又は
(c) 連結するシグナルペプチドを欠くFigure 2 (配列番号:2), Figure 4 (配列番号:4), Figure 6 (配列番号:6), Figure 8 (配列番号:8), Figure 10 (配列番号:10), Figure 12 (配列番号:12), Figure 14 (配列番号:14), Figure 16 (配列番号:16), Figure 18 (配列番号:18), Figure 20 (配列番号:20), Figure 22 (配列番号:22), Figure 24 (配列番号:24), Figure 26 (配列番号:26), Figure 28 (配列番号:28), Figure 30 (配列番号:30), Figure 32 (配列番号:32), Figure 34 (配列番号:34), Figure 36 (配列番号:36), Figure 38 (配列番号:38), Figure 40 (配列番号:40), Figure 42 (配列番号:42), Figure 44 (配列番号:44), Figure 46 (配列番号:46), Figure 48 (配列番号:48), Figure 50 (配列番号:50), Figure 52 (配列番号:52), Figure 54 (配列番号:54), Figure 56 (配列番号:56), Figure 58 (配列番号:58), Figure 60 (配列番号:60), Figure 62 (配列番号:62), Figure 64 (配列番号:64), Figure 66 (配列番号:66), Figure 68 (配列番号:68), Figure 70 (配列番号:70), Figure 72 (配列番号:72), Figure 74 (配列番号:74), Figure 76 (配列番号:76), Figure 78 (配列番号:78), Figure 80 (配列番号:80), Figure 82 (配列番号:82), Figure 84 (配列番号:84), Figure 86 (配列番号:86), Figure 88 (配列番号:88), Figure 90 (配列番号:90), Figure 92 (配列番号:92), Figure 94 (配列番号:94), Figure 96 (配列番号:96), Figure 98 (配列番号:98), Figure 100 (配列番号:100), Figure 102 (配列番号:102), Figure 104 (配列番号:104), Figure 106 (配列番号:106), Figure 108 (配列番号:108), Figure 110 (配列番号:110), Figure 112 (配列番号:112) 又は Figure 114 (配列番号:114)に示されるポリペプチドの細胞外ドメインのアミノ酸配列：
に対して少なくとも８０％のアミノ酸配列同一性を有する単離されたポリペプチド。(a) Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO :) : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Fig ure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or the amino acid sequence of the polypeptide shown in Figure 114 (SEQ ID NO: 114);
(b) Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO :) : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Figure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 114 (SEQ ID NO: 114); or
(c) Figure 2 (SEQ ID NO: 2), Figure 4 (SEQ ID NO: 4), Figure 6 (SEQ ID NO: 6), Figure 8 (SEQ ID NO: 8), Figure 10 (SEQ ID NO :) : 10), Figure 12 (SEQ ID NO: 12), Figure 14 (SEQ ID NO: 14), Figure 16 (SEQ ID NO: 16), Figure 18 (SEQ ID NO: 18), Figure 20 (SEQ ID NO: 20), Figure 22 (SEQ ID NO: 22), Figure 24 (SEQ ID NO: 24), Figure 26 (SEQ ID NO: 26), Figure 28 (SEQ ID NO: 28), Figure 30 (SEQ ID NO: 30), Figure 32 (SEQ ID NO: 32), Figure 34 (SEQ ID NO: 34), Figure 36 (SEQ ID NO: 36), Figure 38 (SEQ ID NO: 38), Figure 40 (SEQ ID NO: 40), Figure 42 (SEQ ID NO: 42), Figure 44 (SEQ ID NO: 44), Figure 46 (SEQ ID NO: 46), Figure 48 (SEQ ID NO: 48), Figure 50 (SEQ ID NO: 50), Figure 52 (SEQ ID NO: 52), Figure 54 (SEQ ID NO: 54) ), Figure 56 (SEQ ID NO: 56), Figure 58 (SEQ ID NO: 58), Figure 60 (SEQ ID NO: 60), Figure 62 (SEQ ID NO: 62), Figure 64 (SEQ ID NO: 64), Figure 66 ( (SEQ ID NO: 66), Fi gure 68 (SEQ ID NO: 68), Figure 70 (SEQ ID NO: 70), Figure 72 (SEQ ID NO: 72), Figure 74 (SEQ ID NO: 74), Figure 76 (SEQ ID NO: 76), Figure 78 (SEQ ID NO: : 78), Figure 80 (SEQ ID NO: 80), Figure 82 (SEQ ID NO: 82), Figure 84 (SEQ ID NO: 84), Figure 86 (SEQ ID NO: 86), Figure 88 (SEQ ID NO: 88), Figure 90 (SEQ ID NO: 90), Figure 92 (SEQ ID NO: 92), Figure 94 (SEQ ID NO: 94), Figure 96 (SEQ ID NO: 96), Figure 98 (SEQ ID NO: 98), Figure 100 (SEQ ID NO: 100), Figure 102 (SEQ ID NO: 102), Figure 104 (SEQ ID NO: 104), Figure 106 (SEQ ID NO: 106), Figure 108 (SEQ ID NO: 108), Figure 110 (SEQ ID NO: 110), Figure 112 (SEQ ID NO: 112) or amino acid sequence of the extracellular domain of the polypeptide shown in FIG. 114 (SEQ ID NO: 114):
An isolated polypeptide having at least 80% amino acid sequence identity to. 軟骨細胞の増殖又は分化を促進するための方法であって、ＰＲＯ６０１８ポリペプチドと前記細胞とを接触させて、前記細胞の増殖又は分化を促進することを含む方法。A method for promoting the proliferation or differentiation of chondrocytes, comprising bringing PRO6018 polypeptide into contact with the cells to promote the proliferation or differentiation of the cells. ヒト微小血管内皮細胞の増殖を促進するための方法であって、ＰＲＯ１３１３，ＰＲＯ２００８０又はＰＲＯ２１３８３ポリペプチドと前記細胞とを接触させて、前記細胞の増殖を促進することを含む方法。A method for promoting proliferation of human microvascular endothelial cells, comprising bringing PRO1313, PRO20080 or PRO21383 polypeptide into contact with said cells to promote proliferation of said cells. ヒト微小血管内皮細胞の増殖を阻害するための方法であって、ＰＲＯ６０７１，ＰＲＯ４４８７又はＰＲＯ６００６ポリペプチドと前記細胞とを接触させて、前記細胞の増殖を阻害することを含む方法。A method for inhibiting the growth of human microvascular endothelial cells, comprising contacting the cells with PRO6071, PRO4487 or PRO6006 polypeptide to inhibit the proliferation of the cells. 哺乳動物における腫瘍の存在を検出する方法であって、(a)前記哺乳動物から得た試験試料及び(b)同細胞型の正常細胞のコントロール試料における表８に示される任意のＰＲＯポリペプチドの発現レベルを比較することを含み、試験試料の前記ＰＲＯポリペプチドの発現がコントロール試料に比較して高いレベルであることによって前記哺乳動物における腫瘍の存在が示される方法。A method for detecting the presence of a tumor in a mammal, comprising: (a) a test sample obtained from said mammal and (b) any PRO polypeptide shown in Table 8 in a control sample of normal cells of the same cell type. Comparing the expression level, wherein the presence of the tumor in the mammal is indicated by a high level of expression of the PRO polypeptide in the test sample relative to the control sample. 前記腫瘍が肺腫瘍、大腸腫瘍、乳腫瘍、前立腺腫瘍、直腸腫瘍、腎腫瘍又は肝腫瘍である、請求項２３の方法。24. The method of claim 23 , wherein the tumor is a lung tumor, a colon tumor, a breast tumor, a prostate tumor, a rectal tumor, a renal tumor or a liver tumor. 内皮細胞管形成を誘発する方法であって、内皮細胞にＰＲＯ２８１、ＰＲＯ１５６０、ＰＲＯ１８９、ＰＲＯ４４９９、ＰＲＯ６３０８、ＰＲＯ６０００、ＰＲＯ１０２７５、ＰＲＯ２１２０７、ＰＲＯ２０９３３又はＰＲＯ３４２７４ポリペプチド、又はそのアゴニストを投与して、前記内皮細胞の管形成を誘発することを含む方法。A method for inducing endothelial cell tube formation, comprising administering to a endothelial cell PRO281, PRO1560, PRO189, PRO4499, PRO6308, PRO6000, PRO10275, PRO21207, PRO20933 or PRO34274 polypeptide, or an agonist thereof, A method comprising inducing formation. 添付図面に示されるヌクレオチド配列の何れかから誘導されるオリゴヌクレオチドプローブ。An oligonucleotide probe derived from any of the nucleotide sequences shown in the accompanying drawings.
JP2002529483A 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding them Expired - Lifetime JP4451059B2 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US22989600P 2000-09-01 2000-09-01
US23062100P 2000-09-05 2000-09-05
US23514700P 2000-09-22 2000-09-22
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
US26187801P 2001-01-12 2001-01-12
US26191001P 2001-01-16 2001-01-16
US26193901P 2001-01-16 2001-01-16
US26215001P 2001-01-16 2001-01-16
US26439501P 2001-01-25 2001-01-25
US26642101P 2001-02-02 2001-02-02
US26762301P 2001-02-09 2001-02-09
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US27439901P 2001-03-09 2001-03-09
US28098201P 2001-04-03 2001-04-03
US28219901P 2001-04-04 2001-04-04
US28212901P 2001-04-04 2001-04-04
US29058901P 2001-05-09 2001-05-09
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021066 WO2002008288A2 (en) 2000-07-20 2001-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/027099 WO2002024888A2 (en) 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006024604A Division JP2006223304A (en) 2000-09-01 2006-02-01 Secreted and transmembrane polypeptide and nucleic acid encoding same

Publications (3)

Publication Number Publication Date
JP2004526412A JP2004526412A (en) 2004-09-02
JP2004526412A5 true JP2004526412A5 (en) 2010-01-28
JP4451059B2 JP4451059B2 (en) 2010-04-14

Family

ID=27585542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002529483A Expired - Lifetime JP4451059B2 (en) 2000-09-01 2001-08-29 Secreted and transmembrane polypeptides and nucleic acids encoding them
JP2006024604A Pending JP2006223304A (en) 2000-09-01 2006-02-01 Secreted and transmembrane polypeptide and nucleic acid encoding same

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006024604A Pending JP2006223304A (en) 2000-09-01 2006-02-01 Secreted and transmembrane polypeptide and nucleic acid encoding same

Country Status (5)

Country Link
EP (1) EP1341814A2 (en)
JP (2) JP4451059B2 (en)
AU (2) AU2002216610A1 (en)
CA (2) CA2632702A1 (en)
WO (1) WO2002024888A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
EP1133558B2 (en) 1998-11-27 2016-04-13 UCB Pharma S.A. Compositions and methods for increasing bone mineralization
EP1661997A1 (en) * 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004520005A (en) * 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー Osteolevin gene polymorphism
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
NZ527087A (en) 2001-01-12 2008-09-26 Genetics Inst Llc Type 2 cytokine receptor and nucleic acids encoding same
EP1406928B1 (en) * 2001-07-19 2010-04-14 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
FR2844713A1 (en) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Use of inhibitor of FLJ protein, for treatment and prevention of e.g. cancer, diabetic retinopathy or arthritis, also new protein, nucleic acid and their inhibitors
JP2006512923A (en) * 2002-10-18 2006-04-20 エルジー ライフサイエンス リミテッド Cancer-related gene family
ES2586401T3 (en) 2003-06-16 2016-10-14 Ucb Pharma S.A. Specific sclerostin antibodies and methods to increase bone mineralization
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
EP2494362B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Prostate tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
EP2383578A1 (en) * 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
PT3195880T (en) 2010-05-14 2020-02-21 Amgen Inc High concentration anti-sclerostin antibody formulations
MX2013010011A (en) 2011-03-01 2014-10-24 Amgen Inc Sclerostin and dkk-1 bispecific binding agents.
KR20140018315A (en) 2011-03-25 2014-02-12 암젠 인크 Anti-sclerostin antibody crystals and formulations thereof
DK2739311T3 (en) 2011-08-04 2018-04-23 Amgen Inc Method of treating bone slit defects
KR20200056473A (en) 2011-12-28 2020-05-22 암젠 인크 Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
EP2869844B2 (en) 2012-07-05 2023-06-21 UCB Pharma S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2019243595A1 (en) 2018-03-30 2020-09-17 Amgen Inc. C-terminal antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073454A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
CA2283299A1 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
EP0998490A2 (en) * 1997-03-25 2000-05-10 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DE19817557A1 (en) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian tumor tissue
CA2328895A1 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides

Similar Documents

Publication Publication Date Title
JP2004526412A5 (en)
JP2006068016A5 (en)
JP2006081548A5 (en)
US20030119135A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030113853A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119121A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119119A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119124A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119126A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119122A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030175900A1 (en) Compositions and methods for the treatment of tumor
AU2002361467B2 (en) Methods and compositions for pearl oyster cultivation
US20030119138A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030170809A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004504061A (en) New members of the EphA receptor family
US20030113856A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN104119448A (en) Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof
CN104119447A (en) Fusion protein containing leucine-rich repetitive sequence, and preparation method and application thereof
US20030119120A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119114A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119141A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030113862A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119136A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119116A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030138901A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same